)
)
Edge16 Oct 2026
Winner, Winner: The Chicken McNugget Story
How a 1940s breeding contest, a Cornell food scientist, and a hedge by Ray Dalio helped McDonald's turn the Chicken McNugget into a fast-food icon.
BioVie
BioVie (BIVI) investor relations material
BioVie Proxy filing summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Proxy filing summary28 Sep, 2026
Executive summary
The annual meeting will be held virtually on November 10, 2026, with voting on director elections, auditor ratification, and an amendment to the equity incentive plan.
Shareholders of record as of September 21, 2026, are eligible to vote on the proposals.
The Board recommends voting in favor of all proposals and director nominees.
Voting matters and shareholder proposals
Proposals include electing six directors, ratifying EisnerAmper LLP as auditor for FY 2027, and amending the 2019 Omnibus Equity Incentive Plan to increase available shares from 399,509 to 3,100,000.
Voting is conducted online, by phone, or by mail, with detailed instructions provided.
Shareholders may submit proposals and nominations for the 2027 annual meeting between August 12 and September 11, 2027.
Board of directors and corporate governance
The Board consists of six members, all current directors, with a mix of industry, finance, and scientific expertise.
Five directors are considered independent under Nasdaq standards.
The Board has Audit, Compensation, and Nominating and Corporate Governance Committees, each composed solely of independent directors.
The Board held eight meetings in FY 2026, with high attendance.
A Code of Conduct and Ethics is in place, accessible on the company website.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from BioVie
- Bezisterim advances toward Phase 3 as BIV201’s ascites program readies a registration trial.BIVI
Corporate presentation - Bezisterim shows strong efficacy in Long COVID and Parkinson's, with phase III trials planned.BIVIStatus update
- Bezisterim showed significant symptom improvement in Long COVID patients with high baseline burden.BIVIStudy result
- Best efforts IPO seeks $22.7M for neuro and liver drug R&D, with up to 16M shares and warrants.BIVIRegistration filing
- Net loss rose to $22.1M in FY2026; ongoing clinical trials and funding needs raise going concern doubts.BIVIQ4 2026
- Bezisterim improved motor, non-motor symptoms, and biomarkers, supporting Phase III advancement.BIVIStudy result
- Biotech seeks $70M in best efforts IPO to fund R&D amid ongoing losses and litigation risks.BIVIRegistration filing
- Biotech seeks up to $70M via share and warrant offering to fund R&D, facing high risk and dilution.BIVIRegistration filing
- Biotech seeks capital for late-stage neuro and liver drug programs amid ongoing losses and legal risks.BIVIRegistration filing
Next BioVie earnings date
AGM 202610 Nov, 2026
BioVie
Next BioVie earnings date
AGM 202610 Nov, 2026
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Find what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
GAM
GAM
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Ciena
Ciena
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Protean
Protean
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)
Frequently asked questions
BioVie Inc. is a clinical stage biopharmaceutical company based in the United States, focusing on the discovery, development, and commercialization of innovative drugs for the treatment of chronic debilitating conditions. The company's pipeline includes key drug candidates like BIV201 for the treatment of ascites due to chronic liver cirrhosis as well as NE3107, aimed at treating neurodegenerative disorders. NE3107 is in clinical trial for mild to moderate Alzheimer's disease and Parkinson's disease. It is headquartered in Carson City, Nevada, and its shares are listed on the Nasdaq.